Want to see AU:IMR full AI Analyst Report?
IMR Stock Chart & Stats
AU$1.92
AU$0.08(4.17%)
At close: 4:00 PM EDT
AU$1.92
AU$0.08(4.17%)
Day’s Range― - ―
52-Week RangeAU$1.28 - AU$2.25
Previous CloseN/A
Volume934.18K
Average Volume (3M)1.25M
Market Cap
AU$493.04M
Enterprise ValueAU$579.50M
Total Cash (Recent Filing)AU$67.46M
Total Debt (Recent Filing)AU$34.02M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding358,650,630
10 Day Avg. Volume1,111,321
30 Day Avg. Volume1,245,842
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)27.34
Price to Sales (P/S)1042.05
P/FCF Ratio-15.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.20Price Target Upside66.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$2.30M
Bulls Say, Bears Say
Bulls Say
MRI-guided EP SpecializationImricor is focused on a specialized medical-device niche that combines electrophysiology with real-time MRI guidance. This differentiated product focus may support clinical value and create a defensible position as hospitals and centers develop MRI-enabled cardiac procedure capabilities.
Procedure-linked Consumables ModelThe business model links revenue to both site adoption and the number of procedures performed, while single-use catheters and consumables can generate repeat sales. Greater utilization at established centers could therefore provide an expandable revenue base beyond initial system adoption.
Equity Balance-sheet ImprovementThe return to positive equity represents a meaningful improvement from the prior two years and reduces immediate balance-sheet stress relative to that period. Although leverage remains a concern, this stronger equity position provides a better foundation for continuing commercialization than persistent negative equity would.
Bears Say
Weak And Declining RevenueVery low and sharply declining revenue indicates that commercial adoption has not yet reached a scale capable of supporting the cost base. Continued volatility makes operating performance difficult to sustain and leaves the company dependent on future procedure growth to establish meaningful revenue momentum.
Persistent Cash ConsumptionOngoing negative operating and free cash flow shows that the business is not yet self-funding its operations. Continued cash consumption can require additional financing and may constrain investment in commercialization, while the absence of positive cash generation leaves less flexibility if growth takes longer than expected.
Elevated Leverage And Funding RiskDebt materially exceeds the company’s current equity base, increasing refinancing pressure while losses continue. Elevated leverage can also reduce financial flexibility and raise the possibility of dilution or additional funding needs if operating cash flow does not improve enough to support obligations.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh News
IMR FAQ
What was Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price range in the past 12 months?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh lowest share price was AU$1.27 and its highest was AU$2.25 in the past 12 months.
What is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s market cap?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s market cap is AU$493.04M.
When is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s upcoming earnings report date?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s upcoming earnings report date is Feb 24, 2027 which is in 124 days.
How were Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s earnings last quarter?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh released its earnings results on Aug 09, 2026. The company reported -AU$0.028 earnings per share for the quarter, beating the consensus estimate of -AU$0.045 by AU$0.017.
Is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh overvalued?
According to Wall Street analysts Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price is currently Undervalued.
Does Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh pay dividends?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh does not currently pay dividends.
What is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s EPS estimate?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh have?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has 358,650,630 shares outstanding.
What happened to Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price movement after its last earnings report?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh reported an EPS of -AU$0.028 in its last earnings report, beating expectations of -AU$0.045. Following the earnings report the stock price went up 1.508%.
Which hedge fund is a major shareholder of Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh?
Currently, no hedge funds are holding shares in AU:IMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$3.20 (66.67% Upside)
AU$3.20 (66.67% Upside)
Blogger Sentiment
Bullish
AU:IMR Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.21%
12-Months-Change
Fundamentals
Return on Equity
-184.93%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company’s products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution soft tissue imaging of MRI to guide and visualize procedures with exceptional clarity; and Advantage-MR EP Recorder / Stimulator. It also offers Vision-MR Dispersive Electrode to minimize eddy currents induced on the device’s conductive pads during mr scanning. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) Earnings & Revenues
IMR Stock 12 Month Forecast
Average Price Target
AU$3.20
▲(66.67% Upside)
Technical Analysis
Impedimed Limited
―
HeraMED Ltd.
―
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―